Skip to main content
. 2017 Dec 23;9(14):11805–11815. doi: 10.18632/oncotarget.23668

Figure 3.

Figure 3

(A–D) Individual study hazard ratios with pooled estimation for progression-free survival for gefitinib, erlotinib, and afatinib. ORR, overall response rate; PFS, progression-free-survival; OS, overall survival.